Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

NCT06399757 is registered in ClinicalTrials.gov with Apollo Therapeutics Ltd as lead sponsor.

NCT NCT06399757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06399757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
Lead sponsor
Apollo Therapeutics Ltd
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2024
Completion date
July 8, 2026
Enrollment
27 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

appendiceal adenocarcinoma, cholangiocarcinoma, colorectal cancer, endometrial adenocarcinoma, gastric adenocarcinoma, ovarian cancer, pancreatic adenocarcinoma, prostate cancer, triple negative breast cancer